NBIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["BUY now: price trend is bullish (SMA_5 > SMA_20 > SMA_200, MACD histogram positive and expanding) and the stock is holding above the key pivot (~136.9), suggesting momentum is still intact at 138.3.", "Fundamentals support owning it into 2026: 2025/Q3 showed strong acceleration in revenue (+27.78% YoY) and even faster earnings growth (EPS +64.52% YoY), consistent with a high-quality, profitable biotech setup.", "Options market is signaling near-term caution (very put-heavy volume and elevated IV), but that often coincides with event positioning ahead of the 2026-02-11 earnings catalyst rather than a broken tape.", "Intellectia Proprietary Trading Signals\n- AI Stock Picker: no signal on given stock today.\n- SwingMax: No signal on given stock recently."]
["Trend/Momentum: Bullish structure with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200).", "MACD: Histogram at 0.901 (above 0) and expanding, confirming improving upside momentum.", "RSI (6): 62.896 (neutral-to-strong); not overbought, leaving room for continuation.", "Key levels: Pivot 136.919 (near-term line in the sand). Resistance at R1 140.193 then R2 142.216; support at S1 133.646 then S2 131.623.", "Near-term read: With price at 138.3, the setup favors a push toward 140\u2013142 if it holds above ~136.9; a clean break above 140.2 would strengthen the bullish case.", "Pattern-based forward odds (provided): ~60% chance of +2.68% next day, +6.32% next week, +23.05% next month (supports a buy-now bias for an impatient buyer)."]
["Upcoming catalyst: QDEC 2025 earnings on 2026-02-11 after hours (near-term event that can re-rate the stock if results/guide beat).", "Analyst narrative remains constructive around Ingrezza durability and newer growth drivers (e.g., Crenessity launch momentum mentioned by UBS; longer exclusivity assumptions referenced by Mizuho).", "Technical backdrop is supportive: bullish MA stack + positive MACD increases odds that good earnings translate into a breakout above 140\u2013142."]
["Options tape is currently defensive: extreme put-heavy volume suggests traders are leaning toward downside protection into the event window.", "Catalyst pacing concern from Wall Street: Morgan Stanley highlighted limited clinical catalysts until 2027 and potential headwinds over the coming year (tempering near-term multiple expansion).", "Macro tape is risk-off today (S&P 500 -1.02%), which can cap biotech upside even when single-name setups look strong."]
["Latest reported quarter: 2025/Q3.", "Revenue: $794.9M, up 27.78% YoY (strong top-line acceleration).", "Profitability: Net income $209.5M, up 61.40% YoY (operating leverage evident).", "EPS: $2.04, up 64.52% YoY (earnings power improving faster than sales).", "Margins: Gross margin 98.24%, down 0.48% YoY (minor compression, but overall margin level remains exceptionally high)."]
["Recent trend: Price targets have generally moved higher (BofA to $195; H.C. Wainwright to $198; TD Cowen to $200; RBC to $180; Stifel to $188), with a few trims (UBS to $178; Truist to $169).", "Rating mix: Predominantly Buy/Outperform; one notable downgrade (Morgan Stanley to Equal Weight with $175 PT) citing headwinds and fewer near-term catalysts.", "Wall Street pros (bull case): Durable Ingrezza growth/runway, improving pricing outlook (RBC), and incremental growth drivers (e.g., Crenessity launch), with multiple firms modeling higher long-term potential.", "Wall Street cons (bear case): Perceived 2026 headwinds and a thinner clinical catalyst calendar near-term (MS), plus past pipeline disappointment (Phase 2 MDD miss referenced in Nov note) increasing skepticism on certain R&D shots.", "Influential trading check: Hedge funds/insiders show no significant recent trend; no recent congress trading data available."]
